Beeram, M., Tolaney, S. M., Beck, J. T., Dickler, M. N., Conlin, A. K., Dees, C., … Goetz, M. P. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology, 27, vi556. https://doi.org/10.1093/annonc/mdw435.08

Beeram, M., S. M. Tolaney, J. T. Beck, M. N. Dickler, A. K. Conlin, C. Dees, T. L. Helsten, et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” Annals of Oncology 27 (October 1, 2016): vi556. https://doi.org/10.1093/annonc/mdw435.08.

Beeram M, Tolaney SM, Beck JT, Dickler MN, Conlin AK, Dees C, et al. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 2016 Oct 1;27:vi556.

Beeram, M., et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” Annals of Oncology, vol. 27, Oct. 2016, p. vi556. Scopus, doi:10.1093/annonc/mdw435.08.

Beeram M, Tolaney SM, Beck JT, Dickler MN, Conlin AK, Dees C, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Kambhampati SRP, Costigan TM, Chan E, Pant S, Kalinsky K, Burris HA, Becerra CH, Rexer BN, Puhalla SL, Goetz MP. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 2016 Oct 1;27:vi556.